News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Solos Endoscopy, Inc. (SLSE.PK) Begins Marketing the New SteriTAP(TM) Endoscopic Instrument Line



7/13/2012 10:01:00 AM

BOSTON, MA--(Marketwire - July 13, 2012) -

Solos Endoscopy, Inc.'s (PINKSHEETS: SNDY) is pleased to announce that the Company has begun marketing its new endoscopic instrument line, SteriTAP™. Solos' SteriTAP™ Instruments are designed to be the ultimate sterile "take a part" endoscopic instruments of their kind and will be marketed and sold worldwide by Solos Endoscopy.

Solos' SteriTAP™ instruments are also approved to immediately receive the CE Mark, which will allow the product to be marketed in those countries where the CE Mark is required, once Solos Endoscopy receives its proper certifications. The SteriTAP™ instruments are now available and are featured on the Company's website, http://www.solosendoscopy.com/steritap.html. The SteriTAP™ instruments include Dissectors, General Surgery Instruments, Graspers, Gynecology Instruments, Lymphadenectomy Instruments, Needle Holders, Scissors, and Thorascopy Instruments.

According to Reportlinker, the demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market. Endoscopy procedures have become highly effective in the diagnosis, treatment, and management of cancer patients. Many now consider endoscopy to have become the gold standard for cancer diagnosis and treatment, as well as for many other medical conditions.

There are other reasons that minimally invasive surgical (MIS) procedures like endoscopy are gaining ground in the overall medical arena. Endoscopic procedures, in general, have a lower cost than their counterparts in traditional surgery. In some cases, the patient only needs light sedation as opposed to full anesthesia. Reduced post surgery monitoring time is required for patients undergoing endoscopic procedures. Finally, there is usually a significantly reduced period the patient has to stay in the hospital along with reduced ancillary costs associated with a post-surgical hospital stay.

The SteriTAP™ Instrument line is part of the extensive product line of Solos Endoscopy instruments, which are all featured on the Company's website, http://www.solosendoscopy.com/.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the Pink OTC Markets (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.


Contact Information:
Amanda Segersten
rsegersten@solosendoscopy.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES